Lorus patent allowed by U.S. Patent Office
Lorus Therapeutics Inc LOR
Shares issued 120,945,940 Jun 12 close $3.30
Tue 13 Jun 2000 News Release
Mr. Philippe Lacaille reports
A patent was allowed by the United States Patent and Trademark Office to
specifically protect GTI-2501, one of Lorus's lead anticancer drugs.
The patent ("Antitumour Antisense Sequences Directed Against R1 and R2
Components of Ribonucleotide Reductase") was allowed based on the unique
antitumour activity of GTI-2501, which is directly related to the positive
findings of tumour regression in mouse models with human tumours derived
from breast and kidney cancers.
The allowed patent gives Lorus strong protection for the unique composition
of GTI-2501, safeguards Lorus's interests in the anticancer drug GTI-2040,
which is currently in a Phase I/II clinical trial, and insulates Lorus'
technology on the design and use of unique antisense, anticancer drugs that
target the expression of two genes that play critical roles in the
development of cancer.
"This patent acknowledges the outstanding activity of GTI-2501, which
entered into toxicity studies earlier this month. The toxicity studies are
expected to be completed by the end of the year and represent the
achievement of another company milestone," said Philippe G. Lacaille, chair
and chief executive officer. "Upon completion of the toxicity studies, we
expect to file an investigational new drug (IND) submission with the Food
and Drug Administration and then proceed to clinical trials."
Lorus is a biopharmaceutical company focused on the research and
development of cancer therapies. Lorus' goal is to capitalize on its
research, pre-clinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination, to
successfully manage cancer. Through an active acquisition and in-licensing
program, Lorus is building a portfolio of promising anticancer drugs.
Late-stage clinical developments and marketing will be done in cooperation
with strategic pharmaceutical partners. Founded in 1986, Lorus is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on
the NASDAQ OTC BB exchange under the symbol LORFF.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
